Arbutus Biopharma
ABUS
ABUS
114 hedge funds and large institutions have $126M invested in Arbutus Biopharma in 2022 Q4 according to their latest regulatory filings, with 11 funds opening new positions, 48 increasing their positions, 30 reducing their positions, and 23 closing their positions.
Holders
114
Holders Change
-12
Holders Change %
-9.52%
% of All Funds
1.84%
Holding in Top 10
3
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+50%
% of All Funds
0.05%
New
11
Increased
48
Reduced
30
Closed
23
Calls
$3.74M
Puts
$1.77M
Net Calls
+$1.98M
Net Calls Change
+$1.28M
Top Buyers
1 |
WCM
1
Whitefort Capital Management
New York
|
$8.97M |
2 |
RCMNY
2
Rubric Capital Management (New York)
New York
|
$8.08M |
3 |
TSC
3
Two Seas Capital
Rye,
New York
|
$17.5M |
4 |
4
BlackRock
New York
|
$20.3M |
5 |
EMG
5
ETF Managers Group
Summit,
New Jersey
|
$1.49M |